1/5, HEAL Consortium: Establishing Innovative Approaches for the HEALthy Brain and Child Development Study

COVID-19疫情影响了儿童及其父母的身心健康。的 大流行还影响了美国大多数机构进行面对面研究的能力 States.然而，最近的技术进步可能允许许多面对面评估过渡到虚拟评估， 格式.迫切需要开发目前使用的家庭评估的虚拟版本 环境和亲子互动，并同时研究COVID-19疫情对 家庭关系。拟议的项目旨在通过利用正在进行的 美国国立卫生研究院健康大脑和认知发展（六溴环十二烷）研究的三个研究中心的研究工作： 阿肯色州儿童研究所、辛辛那提儿童医院和北卡罗来纳州大学在 查佩尔山。我们将在90位有婴儿的母亲中开发和测试一个虚拟版本的家庭清单 年龄在6-18个月之间。我们将通过亲自执行HOME库存来验证此虚拟版本 对其中45对进行评估。在所有参与者中，我们将使用标准问卷来评估COVID-19 暴露和影响。最后，我们将研究区域和时间变化之间的关联， COVID-19疫情风险、影响和家庭清单的维度。本研究的结果将用于 最后完成可广泛用于未来研究的虚拟家庭清单协议的开发， 包括六溴环十二烷二期研究。

The COVID-19 pandemic has affected the mental and physical health of children and their parents. The pandemic has also affected the ability to conduct in-person research at most institutions across the United States. However, recent technological advances may allow many in-person assessments to transition to virtual formats. There is an urgent need to develop virtual versions of currently used assessments of the home environment and parent-child interactions, and to concurrently study the effect of the COVID-19 pandemic on family relationships. The proposed project seeks to address this urgent need by building upon ongoing research efforts among three sites from the NIH HEALthy Brains and Cognitive Development (HBCD) study: Arkansas Children’s Research Institute, Cincinnati Children’s Hospital, and the University of North Carolina at Chapel Hill. We will develop and test a virtual version of the HOME Inventory in 90 mothers with infants between 6-18 months of age. We will validate this virtual version by performing in-person HOME Inventory assessments in 45 of these dyads. In all participants, we will use standard questionnaires to assess COVID-19 exposure and impact. Finally, we will examine associations between regional and temporal variations in COVID-19 exposure and impact and dimensions of the HOME Inventory. The results of this study will be used to finalize the development of a virtual HOME Inventory protocol that can be widely used in future studies, including the HBCD Phase II study.